Publications in DiVA – Angelica Loskog
-
Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
Part of Journal of Translational Medicine, 2023.
DOI for Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models Download full text (pdf) of Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models
-
The signaling and the metabolic differences of various CAR T cell designs
Part of International Immunopharmacology, 2023.
DOI for The signaling and the metabolic differences of various CAR T cell designs
-
Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
Part of PLOS ONE, 2022.
DOI for Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis Download full text (pdf) of Donor-derived urologic cancers after renal transplantation: A retrospective non-randomized scientific analysis
-
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 429-442, 2022.
DOI for Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition Download full text (pdf) of Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
-
Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
Part of Cancer Imaging, 2022.
DOI for Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy Download full text (pdf) of Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy
-
A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
Part of Scientific Reports, 2021.
DOI for A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer Download full text (pdf) of A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer
-
Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
Part of Frontiers in Veterinary Science, 2021.
DOI for Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up Download full text (pdf) of Adenoviral CD40 Ligand Immunotherapy in 32 Canine Malignant Melanomas-Long-Term Follow Up
-
Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
Part of Cancer Immunology and Immunotherapy, p. 2851-2865, 2021.
DOI for Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy Download full text (pdf) of Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy
-
Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.
Part of Cancer Gene Therapy, p. 1188-1197, 2021.
DOI for Intratumoral immunostimulatory AdCD40L gene therapy in patients with advanced solid tumors.
-
Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
Part of MOLECULAR THERAPY-ONCOLYTICS, p. 508-518, 2021.
DOI for Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes Download full text (pdf) of Systemic immunity upon local oncolytic virotherapy armed with immunostimulatory genes may be supported by tumor-derived exosomes
-
Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
Part of Cancer Gene Therapy, p. 948-959, 2020.
DOI for Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40 Download full text (pdf) of Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40
-
Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
Part of Scientific Reports, 2020.
DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
-
Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma.
Part of Investigational new drugs, p. 1448-1453, 2020.
-
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Part of Frontiers in Immunology, 2020.
DOI for The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses Download full text (pdf) of The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
-
Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
Part of BMC Cancer, 2019.
DOI for Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients Download full text (pdf) of Altered profile of immune regulatory cells in the peripheral blood of lymphoma patients
-
Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
Part of Scientific Reports, 2019.
DOI for Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients Download full text (pdf) of Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients
-
IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-beta, Collagen Type I, and PD-L1/PD-1
Part of Journal of Immunology, p. 787-798, 2019.
-
Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
Part of BMC Research Notes, 2019.
DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
-
A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia
Part of Clinical Cancer Research, p. 6185-6194, 2018.
-
An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
Part of European Journal of Haematology, p. 88-97, 2018.
DOI for An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome Download full text (pdf) of An anergic immune signature in the tumor microenvironment of classical Hodgkin lymphoma is associated with inferior outcome
-
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Part of Frontiers in Immunology, 2018.
DOI for Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients Download full text (pdf) of Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
-
Activating CD40 While Inhibiting IL6R Induces Cytokine Production without PDL1 Upregulation in DCs
Part of Molecular Therapy, p. 54-54, 2017.
-
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
Part of Gene Therapy, p. 92-103, 2017.
DOI for Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment Download full text (pdf) of Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
-
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Part of Journal of Translational Medicine, 2017.
DOI for Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients Download full text (pdf) of Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
-
Adenovirus-mediated CD40L gene transfer increases teffector/tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
Part of Scandinavian Journal of Immunology, p. 337-337, 2017.
-
An oncolytic virus targeting desmoplasia and immune activation in pancreatic cancer
Part of Scandinavian Journal of Immunology, p. 335-335, 2017.
-
Distinct phenotype of CD19-specific CAR T cells generated from healthy donor vs. patient lymphocytes using either IL-7/IL-15 or IL-2
Part of Oncology Research and Treatment, p. 213-213, 2017.
-
Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation
Part of American Journal of Transplantation, p. 472-472, 2017.
DOI for Donor Derived and BK Virus Positive Urologic Cancers After Renal Transplantation
-
Immunological biomarkers correlate to survival in CAR19-treated patients
Part of Scandinavian Journal of Immunology, p. 337-337, 2017.
-
Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
Part of OncoTarget, p. 78573-78587, 2017.
DOI for Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients Download full text (pdf) of Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients
-
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
Part of Cytotherapy, p. 689-702, 2017.
DOI for Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion Download full text (pdf) of Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion
-
Preclinical Evaluation of AdVince, an Oncolytic Adenovirus Adapted for Treatment of Liver Metastases from Neuroendocrine Cancer
Part of Neuroendocrinology, p. 54-66, 2017.
-
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
Part of Clinical Cancer Research, p. 5846-5857, 2017.
-
The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation
Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017.
-
A Clinical Trial Using Third Generation CD19 Targeting CAR T Cells for Relapsed Lymphoma and Leukemia
Part of Molecular Therapy, p. S295-S296, 2016.
-
A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses
Part of Molecular Therapy, p. S206-S206, 2016.
-
An Oncolytic Adenovirus Gene Therapy Targeting Both Tumor Cell Survival and Desmoplasia in Pancreatic Cancer
Part of Molecular Therapy, p. S262-S262, 2016.
-
CD19-targeting third generation CAR T cells for relapsed and refractory lymphoma and leukemia: report from the Swedish phase Ulla trial
Part of CANCER IMMUNOLOGY RESEARCH, 2016.
-
Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
Part of Journal of Translational Medicine, 2016.
DOI for Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer Download full text (pdf) of Gemcitabine reduces MDSCs, tregs and TGF beta-1 while restoring the teff/treg ratio in patients with pancreatic cancer
-
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli
Part of Leukemia research, p. 95-103, 2016.
-
Prognostic Implications Of An Active, Innate Or Anergic Immune Response In The Hodgkin Lymphoma Tumor Microenvironment
Part of Haematologica, p. 3-3, 2016.
-
T cell stimulation with different cytokines results in distinct phenotypes and cytotoxic activity of CD19-specific CART cells
Part of Oncology Research and Treatment, p. 136-136, 2016.
-
CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Part of Human Gene Therapy, p. 498-505, 2015.
DOI for CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
-
CD40L and 4-1BBL immunostimulating gene therapy reduces myeloid-derived suppressor cells (MDSCs) while promoting T and NK cell activation
Part of Human Gene Therapy, p. A53-A53, 2015.
-
CD40L/4-1BBL-expressing oncolytic adenovirus (LOAd703) stimulates human dendritic cell production of Th1 cytokines and antigen-specific T cells
Part of Human Gene Therapy, p. A58-A59, 2015.
-
Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity
Part of Gene Therapy, p. 596-601, 2015.
-
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses
Part of Molecular Cancer Therapeutics, p. 1181-1191, 2015.
-
VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-κB-induced endothelial activation
Part of The FASEB Journal, p. 227-238, 2015.
-
AdCD40L Immunostimulatory Gene Therapy in Combination with Cyclophosphamide Prolongs 6-Months Survival in a Phase I/II Trial for Malignant Melanoma
Part of Molecular Therapy, p. S247-S247, 2014.
-
Antigen Signaling Enhances Proliferation and Cytotoxic Capacity of CD19-Targeting CD28/4-1BB CAR T Cells During Expansion Without Inducing Exhaustion
Part of Molecular Therapy, p. S61-S61, 2014.
-
Assessing tissue damage in multiple sclerosis: a biomarker approach
Part of Acta Neurologica Scandinavica, p. 81-89, 2014.
DOI for Assessing tissue damage in multiple sclerosis: a biomarker approach
-
CAR T Cells Express CD40L and Activates Human Dendritic Cells
Part of Molecular Therapy, p. S61-S61, 2014.
-
Development of Gene Transfer Technology
Part of Human Gene Therapy, p. A3-A4, 2014.
-
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
Part of Cancer Immunology and Immunotherapy, p. 273-282, 2014.
-
Immunostimulating Gene Therapy Using an Oncolytic Adenovirus Armed with CD40 Ligand Potently Kill Tumor Cells, Activates Dendritic Cells and Induces T Cell Responses
Part of Molecular Therapy, p. S253-S254, 2014.
-
Intranasal Delivery of CNS-Retargeted Human Mesenchymal Stromal Cells Prolongs Treatment Efficacy of Experimental Autoimmune Encephalomyelitis
Part of Immunology, p. 431-441, 2014.
-
The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
Part of Journal of Neuroimmunology, p. 153-159, 2014.
-
Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
Part of Journal of Neuroimmunology, p. 141-141, 2014.
DOI for Tim-3 and PD-1: Regulators of adaptive immunity in multiple sclerosis
-
AdCD40L immunostimulatory gene therapy shifts the MDSC- and macrophage profiles and promotes T cell infiltration in the tumor microenvironment
Part of Human Gene Therapy, p. A169-A169, 2013.
-
Enhanced proliferation and tyrosine kinase pathway engagement in 4-1BB domain-containing CAR T cells
Part of Human Gene Therapy, p. A163-A163, 2013.
-
Genetically engineered T cells for the treatment of cancer
Part of Journal of Internal Medicine, p. 166-181, 2013.
DOI for Genetically engineered T cells for the treatment of cancer
-
Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
Part of PLOS ONE, p. e55818-, 2013.
DOI for Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia Download full text (pdf) of Increased Level of Myeloid-Derived Suppressor Cells, Programmed Death Receptor Ligand 1/Programmed Death Receptor 1, and Soluble CD25 in Sokal High Risk Chronic Myeloid Leukemia
-
Nya fotspår
Part of Skor är huvudsaken, p. 20-21, 2013.
-
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma
Part of Journal of immunotherapy (1997), p. 350-358, 2013.
-
AdCD40L: Crossing the Valley of Death?
Part of International Reviews of Immunology, p. 289-298, 2012.
-
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
Part of Journal of Neuroinflammation, p. 112-, 2012.
DOI for CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery Download full text (pdf) of CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery
-
T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?
Part of Immunology, p. 255-260, 2012.
DOI for T Regulatory Cells in B-Cell Malignancy: Tumor Support or Kiss of Death?
-
AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial
Part of Clinical Cancer Research, p. 3279-3287, 2010.
DOI for AdCD40L Immunogene Therapy for Bladder Carcinoma: The First Phase I/IIa Trial
-
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
Part of Journal of immunotherapy (1997), p. 225-235, 2010.
DOI for Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy
-
Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
Part of Human Gene Therapy, p. 1381-1381, 2010.
DOI for Genetically Engineered Cells Target CNS and Cure Experimental Autoimmune Encephalomyelitis
-
T regulatory cells lacking CD25 are increased in MS during relapse
Part of Autoimmunity, p. 590-597, 2010.
DOI for T regulatory cells lacking CD25 are increased in MS during relapse
-
Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition
Part of Journal of immunotherapy (1997), p. 785-792, 2009.
-
Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
Part of Acta Oncologica, p. 391-400, 2009.
DOI for Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue Download full text (pdf) of Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue
-
The Janus faces of CD40 in cancer
Part of Seminars in Immunology, p. 301-307, 2009.
-
CD40L-based cancer therapy: Expert commentary
Part of New Gene Therapy and Cancer Research, 2008.
-
CpG oligonucleotides demonstrate increased therapeutic efficacy compared to BCG in an aggressive orthotopic bladder cancer model
Part of Journal of immunotherapy (1997), p. 34-42, 2008.
-
CpG Therapy is Superior to BCG in an Orthotopic Bladder Cancer Model and Generates CD4+ T-cell Immunity
Part of Journal of immunotherapy (1997), p. 34-42, 2008.
-
Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma
Part of Journal of immunotherapy (1997), p. 377-384, 2008.
DOI for Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma